ICD-10-CM Billable Code

D00.08

Carcinoma in situ of pharynx

Clinical Classification Guidelines

Inclusion Terms

  • Carcinoma in situ of aryepiglottic fold NOS
  • Carcinoma in situ of hypopharyngeal aspect of aryepiglottic fold
  • Carcinoma in situ of marginal zone of aryepiglottic fold

Medical Intelligence & Overview

Carcinoma in situ of the pharynx is a condition where abnormal cells are found in the mucosal lining of the pharynx, the part of the throat that connects the nose and mouth to the esophagus and larynx. 'In situ' indicates that these abnormal cells have not spread beyond the layer of tissue where they originated, making it an early form of potential cancer. This diagnosis specifically refers to non-invasive lesions in parts of the pharynx, including the aryepiglottic fold and hypopharyngeal regions. Recognizing and understanding this condition is essential for early intervention and treatment planning.

Causes & Symptoms

Clinical Causes: Tobacco use, including smoking cigars, pipes, or cigarettes Heavy alcohol consumption Chronic irritation or inflammation of the pharyngeal lining Human papillomavirus (HPV) infection Exposure to environmental pollutants or carcinogens History of Head and Neck cancers

Key Symptoms: Persistent sore throat that does not heal Difficulty swallowing or a sensation of a lump in the throat Unexplained hoarseness or voice changes Persistent sore ears without an apparent ear infection Unintentional weight loss in some cases Nasal congestion or bleeding (less common)

Diagnostic & Treatment

Diagnosis Path: Diagnosis of carcinoma in situ of the pharynx typically involves a comprehensive evaluation, including an endoscopic examination of the throat, where a thin, flexible tube with a camera (called an endoscope) is inserted to visualize the affected areas. Additionally, biopsy samples are often taken during this procedure, where tissue is removed and examined under a microscope to confirm the presence of abnormal cells and determine their nature. Imaging tests such as CT scans or MRI may be used to assess the extent of the lesion and check for spread, although the non-invasive nature of in situ carcinoma means it has not invaded deeper tissues or metastasized.

Treatment Protocols: Treatment strategies for carcinoma in situ of the pharynx aim to remove or destroy the abnormal cells before they develop into invasive cancer. Options include: - **Surgical Removal:** Precise excision of the affected tissue, often through minimally invasive procedures. - **Laser Therapy:** Use of focused light energy to eliminate diseased cells. - **High-Dose Radiation:** Targeted radiation therapy, which can be effective for localized in situ lesions. - **Close Monitoring:** Regular follow-up examinations and biopsies to ensure the lesion has been completely treated and has not recurred. The choice of treatment depends on the lesion's location, size, and patient's overall health, as well as the specialist’s assessment.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is D00.08 a billable ICD-10 code?
Yes, D00.08 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report D00.08?
Clinical documentation must specify the nature of Carcinoma in situ of pharynx and any associated comorbidities for accurate reporting.

Cite this Clinical Reference

Clinical Meta Tags

carcinoma pharynx